Written by Zachary Newland, Founding Partner. Last updated September 29, 2026.

Legitimate Medical Purpose: When a Controlled Substance Prescription Becomes a Federal Crime

On This Page

• What “Legitimate Medical Purpose” Means Under Federal Law
• How Federal Prosecutors Use the Legitimate Medical Purpose Standard
• The Mens Rea Requirement After Ruan v. United States
• Documentation, Prescribing Patterns, and Federal Criminal Exposure
• What to Do if You Face a DEA Inquiry or Federal Investigation
• How Evergreen Attorneys Can Help
• Frequently Asked Questions

A physician, nurse practitioner, or other prescriber who issues a controlled substance prescription outside what the federal government considers a legitimate medical purpose can face prosecution under 21 U.S.C. § 841(a)(1), the same statute used against drug traffickers.

The penalties are severe: years in federal prison, loss of a DEA registration, forfeiture of assets, and permanent damage to a medical career. If you are a prescriber who has received a DEA inquiry, a federal target letter, or any indication of a federal investigation into your prescribing practices, securing experienced federal health care fraud defense counsel should be your first step.

Contact Evergreen Attorneys today at (303) 948-1489 if you are the target of a federal investigation. We will help you develop a confidential case strategy designed to protect your rights from day one.

What “Legitimate Medical Purpose” Means Under Federal Law

The phrase “legitimate medical purpose” is the dividing line between a lawful prescription and a federal drug offense. Under 21 C.F.R. § 1306.04(a), a controlled substance prescription is valid only when it is “issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice.” The regulation places responsibility for proper prescribing on the practitioner and imposes a corresponding responsibility on the pharmacist who fills the prescription.

A prescription that does not meet this standard is not a “prescription” within the meaning of 21 U.S.C. § 829 at all. Instead, the Government treats the act of issuing it as illegal distribution or dispensing of a controlled substance. Holding a valid medical license or DEA registration does not, by itself, satisfy the standard. The question is whether the prescription was clinically justified and issued in the way a practitioner in that field would ordinarily practice.

How Federal Prosecutors Use the Legitimate Medical Purpose Standard

Federal prosecutors build controlled substance prescribing cases under 21 U.S.C. § 841(a)(1), which prohibits knowingly or intentionally manufacturing, distributing, or dispensing a controlled substance except as authorized. Since the Supreme Court’s decision in United States v. Moore, 423 U.S. 122 (1975), a registered practitioner has not been immune from prosecution simply because the prescriptions bore a valid DEA number.

The Government typically uses the “legitimate medical purpose” and “usual course of professional practice” standards from 21 C.F.R. § 1306.04(a) as objective benchmarks. Prosecutors look for patterns such as:

• Prescriptions issued without a documented patient evaluation or examination
• Repeated high-dose opioid or benzodiazepine prescriptions with no evidence of diagnosis or monitoring
• Prescriptions written in exchange for cash payments outside normal billing
• A prescribing volume or pattern that deviates significantly from peers in the same specialty
• Absence of drug screening, pill counts, or prescription drug monitoring program (PDMP) checks
• Patient charts that lack treatment rationale or clinical justification

A single red flag may trigger a DEA audit or inquiry. A pattern of red flags can lead to a healthcare fraud grand jury investigation, an indictment, and prosecution.

Colorado’s Supreme Court-proven Federal Criminal Defense Team.

The Mens Rea Requirement After Ruan v. United States

The most significant recent development in this area of law is Ruan v. United States, 597 U.S. 450 (2022). The Supreme Court held that the “knowingly or intentionally” mens rea requirement in § 841 applies to the statute’s “except as authorized” clause. In practical terms, this means:

1. After a defendant produces evidence that the prescribing conduct was authorized (for example, evidence of a bona fide physician-patient relationship, clinical rationale, or adherence to professional standards), the burden shifts to the government to disprove authorization.
2. The Government must then prove beyond a reasonable doubt that the defendant subjectively knew or intended that the conduct was unauthorized.

Ruan did not create a blanket defense for prescribers. It clarified the level of proof the Government must meet. The Tenth Circuit’s 2026 opinion in Kahn v. United States, No. 25-8004, further addressed how objective criteria, including whether the prescriptions served a legitimate medical purpose and fell within the usual course of professional practice, remain relevant evidence the Government can use to prove that the prescriber knew the conduct lacked authorization:

Kahn argues that authorization is “not a peripheral legal concept[,]. . . [i]t [is] the central dividing line between lawful medical practice and federal felony liability.” Reply Br. at 8. We disagree with this argumentbecause the dividing line between lawful medical practice and federal felony liability is the mens rea requirement in § 841(a)(1), which is to knowingly and intentionally commit the actus reus without authorization. Ruan, 597 U.S. at 467

(emphasis original).

We can and have written entire articles on Ruan before. Suffice it to say, that Ruan gave providers a modest additional legal protection.

The interaction between objective prescribing evidence and the subjective knowledge requirement makes contemporaneous documentation and clinical decision-making critical. This is where a defense will live and die after trial.

A prescriber whose records demonstrate a genuine clinical basis for each prescription is in a fundamentally different position than one whose charts are sparse, inconsistent, or created after the fact.

Documentation, Prescribing Patterns, and Federal Criminal Exposure

Federal investigators and prosecutors rely heavily on prescribing records, patient charts, and data from state prescription drug monitoring programs. The strength or weakness of a prescriber’s documentation often determines whether an investigation escalates to criminal charges.

Records that reflect a genuine physician-patient relationship, a clinically supported reason for the medication, appropriate monitoring, and responsive adjustments to the treatment plan tend to support a legitimate medical purpose defense. Records that are missing, inconsistent, backdated, or that show a pattern of prescribing without clinical justification expose the prescriber to serious criminal risk.

Prescribers should also be aware that DEA administrative actions, such as an order to show cause or an immediate suspension order targeting a DEA registration, can run in parallel with a criminal investigation. Statements made during the administrative process can be shared with the DEA and become part of a larger investigative record.

What to Do if You Face a DEA Inquiry or Federal Investigation

A DEA inquiry, administrative subpoena, search warrant, or federal grand jury subpoena is a serious event that can lead to criminal charges. The steps you take in the first days and weeks can determine the trajectory of the case.

1. Preserve all records immediately. Retain patient charts, prescribing logs, electronic health records, PDMP printouts, communications with staff and patients, office policies, and billing records. Do not alter, backdate, or destroy any document.
2. Stop speaking with investigators. Do not provide substantive responses to DEA agents, federal prosecutors, or investigators until defense counsel has assessed the scope of the inquiry and your potential criminal exposure.
3. Retain federal criminal defense counsel. A prescriber facing a DEA investigation needs an attorney who understands the intersection of 21 U.S.C. § 841, the Ruan mens rea standard, and DEA administrative processes. General healthcare regulatory counsel may not have the federal criminal trial and grand jury experience this situation requires.
4. Do not attempt to “explain” your prescribing in an informal conversation. Statements made to agents, even well-intentioned ones, can be used in a subsequent prosecution. Misstatements to a federal agent can independently violate 18 U.S.C. § 1001.
5. Understand the difference between administrative and criminal tracks. A DEA investigation can result in administrative action against your registration, criminal prosecution, or both. The legal standards, procedures, and consequences differ significantly, and a response strategy must account for both.

How Evergreen Attorneys Can Help

Evergreen Attorneys represents prescribers and healthcare professionals facing federal criminal exposure related to controlled substance prescribing, DEA investigations, federal controlled-substance and drug defense matters, and healthcare fraud investigations. Founding Partner Zachary Newland has appeared as counsel of record in more than 130 federal cases since 2016, with focused experience in federal drug prosecutions, healthcare fraud, and federal grand jury subpoena proceedings.

The firm’s defense work in prescriber cases includes analyzing the Government’s evidence against the legitimate medical purpose and usual-course-of-practice standard. Evergreen Attorneys understand the importance of evaluating the strength of contemporaneous medical records, preparing expert review of prescribing patterns, and building a defense informed by the Ruan mens rea framework.

Evergreen Attorneys handles these matters at the partner level, providing direct attorney involvement from investigation through trial.

Frequently Asked Questions

What is a legitimate medical purpose for a controlled substance prescription?

Under 21 C.F.R. § 1306.04(a), a controlled substance prescription must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice. In practical terms, the prescription should be tied to an actual patient evaluation, a clinically supported diagnosis or condition, and a treatment decision that the prescriber can explain from contemporaneous records. A valid license or a completed office visit alone does not establish that the prescription met the federal standard.

What documentation should a prescriber maintain for a controlled substance prescription?

The record should show the clinical basis for the prescription, including the relevant patient history, evaluation findings, diagnosis or treatment objective, medication rationale, and appropriate follow-up or monitoring. The exact documentation required may also depend on state law, the medication, the condition being treated, and the circumstances of care. Contemporaneous records are generally more probative in a DEA or federal investigation than an explanation reconstructed after investigators raise concerns.

Can a prescriber be federally prosecuted for issuing a controlled substance prescription without a legitimate medical purpose?

Yes. A prescriber may face prosecution under 21 U.S.C. § 841(a)(1) if the Government proves that the person knowingly or intentionally dispensed a controlled substance in an unauthorized manner. In Ruan v. United States, 597 U.S. 450 (2022), the Supreme Court held that the Government must prove the required mens rea as to the unauthorized nature of the conduct after the defendant produces evidence that the conduct was authorized. The legitimate medical purpose and usual-course standards in 21 C.F.R. § 1306.04(a) can provide objective evidence relevant to that question.

When should a prescriber involve federal defense counsel after a DEA inquiry?

A prescriber should consult federal defense counsel as soon as there is any indication of a federal investigation, including a DEA visit, an administrative subpoena, a request for patient records from federal agents, a target letter, or a grand jury subpoena.

Early involvement allows counsel to protect the prescriber’s rights during the investigation, prevent inadvertent statements or document production that could harm the defense, and develop a strategy that addresses both the administrative and criminal dimensions of the inquiry. Waiting until charges are filed significantly limits the options available.

If you are facing a federal investigation, DEA inquiry, or prosecution related to controlled substance prescribing, contact Evergreen Attorneys at (303) 948-1489 for a confidential case evaluation.